Experimental neurologyOct 15, 2024

Lactiplantibacillus plantarum SG5 reduces brain inflammation in a mouse model of Parkinson’s disease through the GLP-1/PGC-1α pathway

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Lactiplantibacillus plantarum SG5 improved motor deficits and reduced dopaminergic neuron loss in a mouse model of Parkinson's disease.

L. plantarum SG5 is associated with reduced levels of the protein α-synuclein in the context of Parkinson's disease.
Treatment with SG5 inhibited the overactivation of immune cells in the substantia nigra, which is linked to neuroinflammation.
SG5 treatment attenuated the disruption of blood-brain and intestinal barriers in the mouse model.
Alterations in gut microbiota composition and structure were observed following SG5 administration.
The decrease in colonic GLP-1 secretion induced by MPTP was reversed with SG5 treatment, alongside increased GLP-1 receptor expression in the substantia nigra.
Inhibition of the GLP-1 receptor or PGC-1α reduced the neuroprotective effects of SG5 in the model.

Simplified

Mounting evidence suggests that alterations in gut microbial composition play an active role in the pathogenesis of Parkinson's disease (PD). Probiotics are believed to modulate gut microbiota, potentially influencing PD development through the microbiota-gut-brain axis. However, the potential beneficial effects of Lactiplantibacillus plantarum SG5 (formerly known as Lactobacillus plantarum, abbreviated as L. plantarum) on PD and its underlying mechanisms remain unclear. In this study, we employed immunofluorescence, Western blotting, ELISA, and 16S rRNA gene sequencing to investigate the neuroprotective effects of L. plantarum SG5 against neuroinflammation in an MPTP-induced PD model and to explore the underlying mechanisms. Our results demonstrated that L. plantarum SG5 ameliorated MPTP-induced motor deficits, dopaminergic neuron loss, and elevated α-synuclein protein levels. Furthermore, SG5 inhibited MPTP-triggered overactivation of microglia and astrocytes in the substantia nigra (SN), attenuated disruption of both blood-brain and intestinal barriers, and suppressed the release of inflammatory factors in the colon and SN. Notably, SG5 modulated the composition and structure of the gut microbiota in mice. The MPTP-induced decrease in colonic GLP-1 secretion was reversed by SG5 treatment, accompanied by increased expression of GLP-1R and PGC-1α in the SN. Importantly, the GLP-1R antagonist Exendin 9-39 and PGC-1α inhibitor SR18292 attenuated the protective effects of SG5 in PD mice. In conclusion, we demonstrate a neuroprotective role of L. plantarum SG5 in the MPTP-induced PD mouse model, which likely involves modulation of the gut microbiota and, significantly, the GLP-1/PGC-1α signaling pathway.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

Lactiplantibacillus plantarum SG5 reduces brain inflammation in a mouse model of Parkinson’s disease through the GLP-1/PGC-1α pathway

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief